

# Primary open-angle glaucoma genes

JH Fingert

## Abstract

A substantial fraction of glaucoma has a genetic basis. About 5% of primary open angle glaucoma (POAG) is currently attributed to single-gene or Mendelian forms of glaucoma (ie glaucoma caused by mutations in *myocilin* or *optineurin*). Mutations in these genes have a high likelihood of leading to glaucoma and are rarely seen in normal subjects. Other cases of POAG have a more complex genetic basis and are caused by the combined effects of many genetic and environmental risk factors, each of which do not act alone to cause glaucoma. These factors are more frequently detected in patients with POAG, but are also commonly observed in normal subjects. Additional genes that may be important in glaucoma pathogenesis have been investigated using quantitative traits approaches. Such studies have begun to identify genes that control the magnitude of important quantitative features of glaucoma that may also be important risk factors for POAG, such as central corneal thickness. Each of these different approaches to study glaucoma genetics is providing new insights into the pathogenesis of POAG. *Eye* (2011) 25, 587–595; doi:10.1038/eye.2011.97

**Keywords:** glaucoma; genetics; POAG

## Genes are important in eye disease

Research breakthroughs have shown that genes have key roles in the pathogenesis of common eye diseases, including age-related macular degeneration,<sup>1–4</sup> Fuchs corneal endothelial dystrophy,<sup>5</sup> exfoliation syndrome,<sup>6</sup> and primary open-angle glaucoma (POAG).<sup>7–9</sup> The recent discovery of important risk factors for these common eye diseases underscores the utility of studying ophthalmic genetics.

The identification of disease-causing genes provides information about the pathogenesis of heritable eye diseases at the most basic level. For example, disease-causing genes may be part

of important biological pathways that once identified may help clarify the mechanisms that lead to disease. The discovery of disease genes will also continue to provide insights into the normal function of the eye.

Discovery of the genes that cause eye disease may also provide useful information for patients and their physicians. Identifying these genes will enable the design of DNA-based tests that may help physicians assess their patient's risk for disease and may also differentiate between clinically similar disorders. Many such tests are already available on both a fee-for-service and research basis (<http://www.genetests.org>). Identification of the specific mutation or mutations that are responsible for a patient's disease not only solidifies the diagnosis, but may also help predict its likely clinical course. Several mutation-specific phenotypes of hereditary eye diseases have already been reported, including glaucoma,<sup>10</sup> retinitis pigmentosa,<sup>11</sup> and Von Hippel Lindau syndrome.<sup>12</sup> Genetic variations may also influence a patient's response to therapeutic interventions and will help guide selection of their clinical and surgical care.

Discovery of the genes that cause disease is a vital step in the development of new treatments for heritable eye conditions. The biological function of a disease-causing gene may in some cases suggest the application of currently available medical and surgical therapies. In other cases, new interventions may be developed to compensate a genetic defect after it is identified. Such gene-directed therapies might include currently available or newly designed medications, gene therapy (replacing a mutant gene with a normal copy), and/or other molecular genetic approaches such as blocking mutant gene expression.<sup>13,14</sup>

Many eye diseases, including glaucoma, are both genetically and mechanistically heterogeneous, meaning that it is unlikely that one therapy will be effective for all forms of a disease. Genetic studies of complex diseases may also provide crucial information for future animal and clinical treatment trials. The most

Department of  
Ophthalmology and Visual  
Sciences, Carver College  
of Medicine, University of  
Iowa, Iowa City, IA, USA

Correspondence: JH Fingert,  
Department of  
Ophthalmology,  
The University of Iowa  
College of Medicine, Iowa  
City, IA 52242, USA  
Tel: +1 319 335 7508;  
Fax: +1 887 434 9041.  
E-mail: [john-fingert@uiowa.edu](mailto:john-fingert@uiowa.edu)

Received: 14 March 2011  
Accepted: 14 March 2011

relevant animal models of eye disease will be those that are designed to have the same genetic defects that are found in human disease. Such animal models would have great value for testing both the safety and efficacy of new therapies. Additionally, researchers may use genetic tests to identify relatively homogeneous populations of study patients for treatment trials or to study patients with the same molecular cause of disease.

### Glaucoma is a heritable disease

The idea that heredity has an important role in glaucoma pathogenesis is not new. Some of the earliest evidence came from reports of large pedigrees in which glaucoma was passed down from generation to generation in a Mendelian pattern that demonstrated that at least some cases of glaucoma have a genetic basis. Twin studies and familial clustering studies have also indicated that some portion of glaucoma is caused by heredity.<sup>15–20</sup> Finally, several domesticated animal breeds, including the DBA/2J mouse (pigmentary glaucoma), cats, and dogs, have been documented to be afflicted by inherited glaucoma.<sup>21–25</sup> Together these data provide strong evidence that genes have an important role in the pathogenesis of glaucoma and provide support for efforts to find these genes.

In the last two decades significant progress has been made in unraveling the genetic basis of POAG. Mutations that lead to POAG can be divided into two groups with very distinct characteristics (Table 1). One class of mutations are capable of ‘causing’ POAG on their own with little influence from other genes or the environment. These single-gene forms of glaucoma are responsible for disease that is transmitted as a Mendelian trait, often with an autosomal dominant inheritance pattern. Individuals that carry these types of mutations almost always develop POAG and these mutations are rarely observed in subjects with normal eyes. Mutations in the *myocilin* (*MYOC*) and *optineurin* (*OPTN*) genes are examples of mutations that ‘cause’ POAG and are discussed in more detail below. The other class of

mutations, ‘risk alleles’, may promote the development of POAG when combined with other glaucoma risk alleles and environmental factors but do not cause disease on their own (Table 1). These alleles or genetic risk factors are statistically more common in POAG patients, although they are very frequently detected in both patients and controls. In this report, the current state of our knowledge of the genetic basis for glaucoma is reviewed, including glaucoma causing genes, glaucoma genetic risk factors, and quantitative traits related to the development of glaucoma.

### POAG-causing genes (Mendelian—single-gene disease)

#### *Myocilin* (*MYOC*, OMIM #601652)

*Myocilin* was the first gene to be associated with POAG, and mutations in this gene are the most common cause of glaucoma with a known molecularly defined basis. Glaucoma-causing mutations in *myocilin* were first detected in linkage-based studies of large pedigrees with juvenile open angle glaucoma (JOAG).<sup>7,27</sup> *Myocilin* mutations have since been found in 3–4% of POAG patients<sup>7,26</sup> and a range of glaucoma-associated *myocilin* mutations have now been cataloged in review articles<sup>28,29</sup> and online at <http://www.myocilin.com>. In most cases, *myocilin*-associated glaucoma appears to be transmitted as an autosomal dominant trait and is associated with markedly elevated IOP.

*Myocilin* and JOAG. Glaucoma-causing mutations have been identified in many JOAG pedigrees with glaucoma that is inherited as an autosomal dominant trait. *Myocilin* mutations are relatively common in patients with JOAG, and have been detected in 8–36% of patients in published case series.<sup>30–32</sup> The likelihood of detecting *myocilin* mutations in subjects with JOAG appears to be greater in patients with stronger family histories of glaucoma than in patients with apparently sporadic glaucoma.

**Table 1** Two classes of POAG mutations

Features of mutations	Glaucoma-‘causing’ mutations		Glaucoma risk alleles	
	Generally	<i>Myocilin</i> (GLN368Stop)	Generally	Chromosome 7q31 risk allele (rs4236601A)
Frequency in POAG cohorts	Low	1.6%	Common	28.7%
Frequency in normal cohorts	Usually absent	0.13%	Common	22.8%
Likelihood of POAG in those with mutations	High	98.6%	Low	Odds ratio 1.36

This table highlights the differences between mutations that primarily ‘cause disease’ on their own (such as the GLN368STOP mutation) and those that contribute to the overall risk for developing disease (such as the chromosome 7q31 risk allele). The data for the *myocilin* mutation (GLN368STOP) are from <http://www.myocilin.com> and Fingert *et al.*<sup>26</sup> The data for the chromosome 7q31 risk allele are from Thorleifsson *et al.*<sup>8</sup>

*Myocilin and POAG.* *Myocilin* mutations are also co-inherited with POAG in an autosomal dominant pattern and have been detected in cohorts of POAG patients from around the world. However, due to the later onset of disease, the POAG pedigrees are smaller and the mode of inheritance is not as obvious as is observed with JOAG families.<sup>26</sup> Many mutations are only observed in specific geographic or ethnic populations, but one *myocilin* mutation (GLN368STOP) has been detected in nearly all of the examined POAG populations, including African-Americans and Caucasians from the United States, Canada, Australia, Europe, and South America.<sup>28</sup> This most common *myocilin* mutation has not, however, been observed in Asian glaucoma patients. Some studies have suggested that a founder effect may be responsible for the high relative frequency of the GLN368STOP mutation in some populations.<sup>26</sup>

*Myocilin genotype–phenotype correlations.* Individual *myocilin* mutations have been associated with specific clinical features of *myocilin*-related glaucoma such as age of diagnosis, maximum intraocular pressure (IOP), and response to medical therapy. The best correlations between genotype and phenotype come from the two classes of mutations that have been detected in most glaucoma patients: *myocilin* mutations that cause JOAG and the GLN368STOP mutation. In addition to having an earlier age of onset, the *myocilin* mutations that cause JOAG are also associated with higher IOP and greater resistance to medical therapies than mutations that cause POAG. Although a number of reports have shown that subjects with JOAG respond poorly to medical treatment and generally require surgical interventions,<sup>33,34</sup> a study by Graul *et al*<sup>35</sup> has shown that POAG patients with a GLN368STOP *myocilin* mutation have similar rates of laser trabeculoplasty and surgery as POAG patients with no *myocilin* mutations. However, another study by Craig *et al*<sup>36</sup> reported that glaucoma patients with GLN368STOP mutations had increased rates of filtration surgery compared with patients with no *myocilin* mutations.

*Myocilin and glaucoma pathogenesis.* *Myocilin* was first identified as a glaucoma gene in 1997, but we still know little about the normal function of the protein it encodes. In health, *myocilin* protein is produced by many cell types of the eye and is secreted into the aqueous humor for an unknown purpose. Studies of both cell culture and human tissue have shown that the abnormal protein that is produced by *myocilin* mutations is poorly secreted and is retained within trabecular meshwork cells.<sup>37–40</sup> Accumulation of abnormal *myocilin* protein may be toxic to trabecular meshwork cells and may lead to their dysfunction or death, which may ultimately produce

decreased aqueous outflow, elevated IOP, and glaucoma.<sup>41,42</sup> Animal models harboring *myocilin* mutations have been developed and are beginning to reveal the specific molecular steps that lead from mutations in *myocilin* to the elevated IOP that is characteristic of *myocilin*-related glaucoma.<sup>43–45</sup>

### ***Optineurin (OPTN, OMIM #602432)***

*Optineurin* was identified as a glaucoma-causing gene through investigations of a large normal tension glaucoma (NTG) pedigree. The dominantly inherited glaucoma in this family was shown to be caused by a GLU50LYS mutation in the *optineurin* gene.<sup>9,46</sup> Subsequently, most studies of *optineurin* in large populations of glaucoma patients have suggested that mutations in this gene may be responsible for up to 1.5% of NTG cases.<sup>47–49</sup> The strongest data linking mutations in *optineurin* with glaucoma are focused on the GLU50LYS mutation. The links between other *optineurin* mutations and glaucoma are more complex, as these mutations are associated with glaucoma in some but not all populations. For example, the MET98LYS variant in *optineurin* is statistically more common in NTG patients than control subjects in some Caucasian and Asian populations,<sup>47,50,51</sup> but not in others.<sup>47,52,53</sup> Overall, mutations in *optineurin* do not appear to be associated with cases of POAG that have elevated IOP in most<sup>47,48,52,54–57</sup> but not all populations.<sup>51,55</sup> The significance of some *optineurin* variations appears to depend upon the population in which they are observed.

*Optineurin and glaucoma pathogenesis.* The mechanism by which *optineurin* causes glaucoma has been investigated using *in vitro* and *in vivo* studies. There is some evidence that *optineurin* may have neuro-protective effects that are reduced or eliminated by disease-causing mutations. Overexpression of wild-type *optineurin* appears to provide some protection from apoptosis induced by oxidative stress in a cell culture system. This protective effect is not observed with overexpression of mutant *optineurin* protein.<sup>58</sup> More recently, experiments with transgenic mice have demonstrated that the GLU50LYS mutation in *optineurin* leads to apoptosis of retinal ganglion cells. Further studies of these mice have suggested that *optineurin*-mediated glaucoma may result from a disruption of an interaction between *optineurin* and a GTP-binding protein, Rab8, and its effects on protein trafficking.<sup>59</sup>

### ***TANK-binding kinase-1 (TBK1)***

*TBK1* encodes a kinase that regulates the expression of genes in the NF- $\kappa$ B signaling pathway. Copy number

variations (duplications) that encompass the *TBK1* gene were recently shown to be associated with glaucoma through family-based studies.<sup>60</sup> First, linkage analysis of a large African-American NTG pedigree mapped a new glaucoma gene to chromosome 12q14. Subsequent investigations of this part of the genome demonstrated that all family members with glaucoma possessed a duplication of the *TBK1* gene and some neighboring genes. This particular duplication was never seen in control subjects. When a cohort of additional NTG patients were similarly tested for copy number variations, 2 (1.3%) of 152 NTG patients were found to have unique but overlapping duplications of chromosome 12q14 that also spanned the *TBK1* gene.<sup>60</sup> These data suggest that an extra copy of *TBK1* leads to NTG and may be responsible for some fraction of sporadic-appearing NTG cases.

The role of *TBK1* in glaucoma pathogenesis is also supported by previous studies of *optineurin*, the only other known NTG gene. In 2008, Morton *et al*<sup>61</sup> showed that the protein encoded by *optineurin* interacts with *TBK1* and that this interaction is influenced by an *optineurin* mutation (GLU50LYS) that was previously shown to be associated with glaucoma. This interaction with *optineurin*, a known NTG gene, further supports a role for *TBK1* in glaucoma pathogenesis.

Little is known about how copy number variations in *TBK1* might cause glaucoma. The interaction between *TBK1* and genes in the NF- $\kappa$ B signaling pathway may influence important processes that are involved in the pathogenesis of glaucoma, including apoptosis and modulation of the immune system. Initial studies have shown that *TBK1* is expressed in human retinal ganglion cells and that duplication of this gene significantly alters its expression in cultured fibroblasts.<sup>60</sup> Therefore, it is a plausible hypothesis that copy number variations of *TBK1* cause a dysregulation of NF- $\kappa$ B signaling that ultimately leads to apoptosis of retinal ganglion cells and the development of NTG.

#### **WD-repeat domain 36 (WDR36, OMIM 609669)**

Linkage analysis of two POAG pedigrees mapped a glaucoma gene to chromosome 5q22, and subsequent studies of genes in this locus suggested that mutations in *WDR36* might cause some cases of POAG.<sup>62</sup> However, many subsequent studies failed to confirm this link.<sup>63–65</sup> Furthermore, two additional POAG pedigrees have been identified with glaucoma that is linked to the same chromosome 5q22 locus, but these pedigrees were found to harbor no *WDR36* mutations. These results suggest the presence of a different glaucoma gene in the region.<sup>66,67</sup> Nonetheless, a few studies have identified rare *WDR36* variants that may be associated with POAG in some

populations. As a result, there is continued controversy over the role of *WDR36* in glaucoma pathogenesis.

Although *WDR36* was initially identified in studies focused on genes that 'cause' Mendelian forms of POAG, some researchers have investigated the possibility that variants in this gene may either contribute to the risk for developing complex, polygenic forms of glaucoma<sup>68,69</sup> or influence the severity of disease.<sup>63</sup> The mechanism by which such common *WDR36* variants might contribute to the risk for POAG is unknown. However, some common variants of *WDR36* have been shown to alter cell viability in yeast<sup>70</sup> and axon growth in mouse retinal ganglion cells.<sup>71</sup>

#### **Genetic risk factors for glaucoma (complex genetic disease)**

Family-based studies have been successful in discovering a number of genes that are capable of causing POAG with minimal influence from other genes or the environment. However, the known glaucoma-causing genes are together responsible for <5% of POAG cases. Many of the remaining cases of POAG are likely due to the combined action of several genes and environmental factors. In the last several years, researchers have searched for genetic risk factors that contribute to the development of glaucoma by conducting genome-wide association studies (GWAS). These investigations compare the genomes of POAG patients and control subjects with normal eyes to find gene sequences that are statistically more common in patients with glaucoma. Association studies have been very effective in discovering important risk factors for other inherited eye conditions such as age-related macular degeneration,<sup>1–4</sup> Fuchs endothelial corneal dystrophy,<sup>5</sup> and exfoliation syndrome.<sup>6</sup>

More recently, association studies have begun reporting genetic risk factors for POAG. Some of these discoveries are discussed below.

#### **S1 RNA binding domain 1 (SRBD1)**

In a recent GWAS analyzing the genetic risk factors for NTG in a Japanese population, the strongest signal was on chromosome 2 and spanned the *SRBD1* gene.<sup>72</sup> The most tightly associated genetic marker (rs3213787) in this GWAS is located within intron 17 of *SRBD1* and produced a *P*-value of  $2.5 \times 10^{-9}$  and an odds ratio of 2.80 for NTG. The high-risk allele of this genetic marker influences the expression of *SRBD1* and may be the source of risk for NTG at this locus. Both the function of *SRBD1* and the mechanism by which variants in this gene might increase the risk for NTG are unknown. However, it has been hypothesized that *SRBD1*'s binding properties may promote the development of NTG



through their proposed influence on protein synthesis, growth, and apoptosis in retinal ganglion cells.<sup>72</sup> This association has not yet been confirmed by replication studies.

#### ***Elongation of long-chain fatty acids family member 5 (ELOVL5)***

A second association with NTG in Japan was also reported between glaucoma and genetic markers on chromosome 6 spanning the *ELOVL5* gene.<sup>72</sup> The most significant association was identified with a genetic marker located within the 3' untranslated region of *ELOVL5* (rs735860), which produced a *P*-value of  $4.14 \times 10^{-6}$  and an odds ratio for NTG of 1.69. The *ELOVL5* gene encodes a protein that is involved in the production of long-chain polyunsaturated fatty acids (LCPUFAs). The risk allele of rs735860 influences the expression of *ELOVL5*<sup>72</sup> and it has been suggested that this effect might lead to increased LCPUFAs and promote apoptosis in retinal ganglion cells that leads to NTG. Replication studies of this association have not yet been reported.

#### ***Caveolin 1/Caveolin 2 (CAV1/CAV2)***

A large GWAS conducted by Thorleifsson *et al*<sup>8</sup> mapped a risk factor for POAG to a region of chromosome 7q31 that encompasses two genes, *caveolin 1* (*CAV1*) and *caveolin 2* (*CAV2*). The risk allele in this locus is presumed to lie within either *CAV1* or *CAV2*, but has not yet been identified. One genetic marker in this locus, rs4236601, produced a *P*-value of  $5.0 \times 10^{-10}$  and an odds ratio of 1.36 for POAG in a discovery cohort from Iceland.<sup>8</sup> The same study included additional large cohorts of POAG patients and controls from Sweden, United Kingdom, Australia, Australia, and China. Pooled analyses of these replication cohorts confirmed the association with statistically significant, but much less remarkable *P*-values (0.0015 in Caucasian and 0.003 in Chinese cohorts) than what was observed in the discovery cohort from Iceland. Moreover, no association was detected in some of the individual replication cohorts in this study, such as those from the United Kingdom.<sup>8</sup> More recently, a second study with a single POAG cohort from the United States also failed to detect an association between glaucoma and rs4236601.<sup>73</sup> These data suggest that the POAG risk factor in the caveolins locus may be more important in some patient populations than in others.

The mechanism by which caveolin genes might confer risk for glaucoma is presently unclear. These genes encode proteins expressed in ocular tissues that are critical in glaucoma pathogenesis, including the trabecular meshwork and Schlemm's canal.<sup>73</sup> The

caveolins form invaginated structures of cell membranes (caveolae) that are believed to influence transport of macromolecules across membranes and modulate signal pathways.<sup>74</sup> It has been proposed that risk for glaucoma might be increased by caveolin variants that alter TGF- $\beta$  or nitric oxide signaling.<sup>8</sup>

A number of additional risk alleles for POAG have been reported that are noteworthy but are awaiting confirmatory reports. These potential risk alleles have been cataloged elsewhere.<sup>75</sup>

#### ***Summary***

Risk alleles of major effect have been detected for several important eye diseases. For example, the complement factor H risk allele has an odds ratio of 2.45 and a population attributable risk of 43% for macular degeneration.<sup>3</sup> The *LOXL1* risk allele produces an odds ratio of 20.10 for exfoliation syndrome with a population attributable risk of 99%.<sup>6</sup> Similarly, an odds ratio of 5.5 and population attributable risk of 61% for Fuch's corneal endothelial dystrophy are produced by a risk factor in the *TCF4* gene.<sup>5</sup> Moreover, these risk alleles have been detected in most patient populations that have been tested. In contrast, no risk alleles of major effect for POAG have been detected to date. Association studies of POAG have identified risk alleles of smaller effect with more modest odds ratios and population attributable risks. The results of these initial GWAS suggest that POAG may be caused by the combined small effects of a very large number of genetic factors.

#### ***Quantitative traits approaches to the genetics of POAG***

Many important features of glaucoma are quantitative traits. For example, POAG is defined by the quantitative assessment of cup-to-disc ratio and visual field defects. IOP is another vital quantitative measure for establishing and assessing treatment goals. More recently, central corneal thickness (CCT) has been established as another important quantitative measure in the assessment of glaucoma.

The magnitudes of most quantitative traits are generally controlled by a number of genes as well as environmental influences. Large studies of twins, siblings, and small pedigrees have shown that CCT,<sup>76,77</sup> cup-to-disc ratio,<sup>78–81</sup> and IOP<sup>80–84</sup> are all highly heritable traits and are likely determined in part by the actions of genes. Investigations to identify these genes will likely provide important insights into the pathophysiology of glaucoma. The same genes that determine the magnitudes of individual features of glaucoma are likely to be contributors to the overall risk for developing glaucoma as well.

Three recent large-scale GWAS have identified genetic factors that influence the magnitude of CCT.<sup>85–87</sup> A segment of chromosome 16q near the gene *ZNF469* was identified as an important quantitative traits locus for CCT in all three studies. *ZNF469* is an excellent candidate for regulating CCT as mutations in this gene were previously linked with brittle cornea syndrome (BCS OMIM #229200).<sup>88</sup> The specific variant in *ZNF469* that influences corneal thickness has not been identified; however, it has been estimated that it may be responsible for 1.29% of CCT variance. Other genetic factors that influence CCT<sup>85–87</sup> have been discovered, including variants in collagen genes (*COL5A1* and *COL8A2*). Detection of the first genetic factors for CCT is a significant advance and has paved the way for more discoveries. Although previous heritability studies clearly demonstrated that genes have a major influence on CCT, the number of genes that are important determinants of CCT is unclear. However, initial studies have found factors that exert a relatively modest influence on CCT and suggest that many more factors remain to be discovered.

## Summary

A range of different types of genetic discoveries have been reported for glaucoma, which may be categorized as POAG-causing mutations or POAG genetic risk factors. Some cases of POAG can be attributed to the action of a single POAG-causing gene, whereas others are likely due to the interaction of many POAG genetic (and environmental) risk factors. It is important to distinguish between these types of factors to best interpret their clinical significance for both individual patients and large populations.

Rare POAG-causing mutations in genes such as *myocilin*, *optineurin*, and *TBK1* lead to disease without significant influence from other factors and are responsible for ~5% of POAG cases. Discovery of these POAG-causing genes has facilitated both the advancement of patient care and future glaucoma research strategies. Genetic testing for myocilin and optineurin mutations may provide select patients and their ophthalmologists with clinically useful data because these mutations are very rarely observed in people without glaucoma. The discovery of POAG-causing genes has also provided researchers with tools to engineer relevant animal models of glaucoma. Several mouse models of myocilin and optineurin-related POAG have been generated and will facilitate further studies of the biological mechanisms of vision loss in glaucoma.<sup>43,44,59,89</sup>

In contrast, for complex genetic forms of disease, an individual genetic risk factor for POAG is not capable of

causing glaucoma on its own, and most carriers of this type of risk factor will never develop glaucoma. In the future, when more of these risk factors have been identified, testing patients for the presence of several genetic factors may have more clinical utility for predicting which patients are at highest risk for developing disease and need closer surveillance. Similarly, physicians may someday be able to improve clinical outcomes by customizing treatment regimens with such genetic tests.

It is very likely that additional important genetic factors for glaucoma will be discovered in the not too distant future. More large families with POAG are currently being studied with linkage analysis and hold the potential of discovering additional disease-causing glaucoma genes. Similarly, the largest GWAS of POAG that are underway will provide greater potential than ever to identify new important genetic factors that contribute to the complex forms of glaucoma. There is great promise that these studies will continue to clarify the role of genes in POAG and begin to reshape the way in which we diagnose and treat glaucoma.

## Conflict of interest

The author declares no conflict of interest.

## Acknowledgements

This work was supported by NIH grants RO1EY018825 and K08 EY017698. I would also like to acknowledge the thoughtful discussions with Robert F Mullins, Markus H Kuehn, and Maurine Neiman.

## References

- 1 Klein R, Zeiss C, Chew E, Tsai J, Sackler R, Haynes C *et al.* Complement factor H polymorphism in age-related macular degeneration. *Science* 2005; **308**: 385–389.
- 2 Edwards AO, Ritter III R, Abel KJ, Manning A, Panhuysen C, Farrer LA. Complement factor H polymorphism and age-related macular degeneration. *Science* 2005; **308**: 421–424.
- 3 Haines JL, Hauser MA, Schmidt S, Scott WK, Olson LM, Gallins P *et al.* Complement factor H variant increases the risk of age-related macular degeneration. *Science* 2005; **308**: 419–421.
- 4 Hageman G, Anderson D, Johnson L, Hancox L, Taiber A, Hardisty L *et al.* A common haplotype in the complement regulatory gene factor H (HF1/CFH) predisposes individuals to age-related macular degeneration. *Proc Natl Acad Sci USA* 2005; **102**: 7227–7232.
- 5 Baratz KH, Tosakulwong N, Ryu E, Brown WL, Branham K, Chen W *et al.* E2-2 protein and Fuchs's corneal dystrophy. *N Engl J Med* 2010; **363**: 1016–1024.
- 6 Thorleifsson G, Magnusson KP, Sulem P, Walters GB, Gudbjartsson DF, Stefansson H *et al.* Common sequence

- variants in the LOXL1 gene confer susceptibility to exfoliation glaucoma. *Science* 2007; **317**: 1397–1400.
- 7 Stone EM, Fingert JH, Alward WL, Nguyen TD, Polansky JR, Sunden SL *et al.* Identification of a gene that causes primary open angle glaucoma. *Science* 1997; **275**: 668–670.
- 8 Thorleifsson G, Walters GB, Hewitt AW, Masson G, Helgason A, DeWan A *et al.* Common variants near CAV1 and CAV2 are associated with primary open-angle glaucoma. *Nat Genet* 2010; **42**: 906–909.
- 9 Rezaie T, Child A, Hitchings R, Brice G, Miller L, Coca-Prados M *et al.* Adult-onset primary open-angle glaucoma caused by mutations in optineurin. *Science* 2002; **295**: 1077–1079.
- 10 Alward WL, Fingert JH, Coote MA, Johnson AT, Lerner SF, Junqua D *et al.* Clinical features associated with mutations in the chromosome 1 open-angle glaucoma gene (GLC1A). *N Engl J Med* 1998; **338**: 1022–1027.
- 11 Berson EL, Rosner B, Sandberg MA, Dryja TP. Ocular findings in patients with autosomal dominant retinitis pigmentosa and a rhodopsin gene defect (Pro-23-His). *Arch Ophthalmol* 1991; **109**: 92–101.
- 12 Webster AR, Maher ER, Bird AC, Moore AT. Risk of multisystem disease in isolated ocular angioma (haemangioblastoma). *J Med Genet* 2000; **37**: 62–63.
- 13 Doudna JA, Cech TR. The chemical repertoire of natural ribozymes. *Nature* 2002; **418**: 222–228.
- 14 Sullenger BA, Gilboa E. Emerging clinical applications of RNA. *Nature* 2002; **418**: 252–258.
- 15 Benedict TWG. *Abhandlungen aus dem Gebiete der Augenheilkunde*. Breslau: L Freunde, 1842.
- 16 Arlt CF. *Die Krankheiten des Auges für praktische Ärzte*. Vol. 1/2. Credner & Kleinbub: Prague, 1853.
- 17 Teikari JM, Airaksinen PJ, Kaprio J, Koskenvuo M. Primary open-angle glaucoma in 2 monozygotic twin pairs. *Acta Ophthalmol (Copenh)* 1987; **65**: 607–611.
- 18 Kurten H, Halle S. Ein 81 jähriges, eineiiges zwillingsbruderpaar. *Arch Rassen Gessell Biol* 1934; **28**: 38–49.
- 19 Westerland KE. *Clinical and genetic studies on the primary glaucoma diseases*. Busck: Copenhagen, 1947.
- 20 Biró I. Notes on the heredity of glaucoma. *Ophthalmologica* 1939; **98**: 43–50.
- 21 John SW, Smith RS, Savinova OV, Hawes NL, Chang B, Turnbull D *et al.* Essential iris atrophy, pigment dispersion, and glaucoma in DBA/2J mice. *Invest Ophthalmol Vis Sci* 1998; **39**: 951–962.
- 22 Anderson MG, Smith RS, Hawes NL, Zabaleta A, Chang B, Wiggs JL *et al.* Mutations in genes encoding melanosomal proteins cause pigmentary glaucoma in DBA/2J mice. *Nat Genet* 2002; **30**: 81–85.
- 23 McLellan GJ, Betts DM, Sigle K, Grozdanic SD. Congenital glaucoma in the simease cat—a novel spontaneous animal model for glaucoma research. *Invest Ophthalmol Vis Sci* 2005; **46**, E-Abstract 134.
- 24 Gelatt KN, Peiffer Jr RL, Gwin RM, Sauk Jr JJ. Glaucoma in the beagle. *Trans Sect Ophthalmol Am Acad Ophthalmol Otolaryngol* 1976; **81**(4 Part 1): OP636–OP644.
- 25 Grozdanic SD, Kecova H, Harper MM, Nilaweera W, Kuehn MH, Kardon RH. Functional and structural changes in a canine model of hereditary primary angle-closure glaucoma. *Invest Ophthalmol Vis Sci* 2010; **51**: 255–263.
- 26 Fingert JH, Heon E, Liebmann JM, Yamamoto T, Craig JE, Rait J *et al.* Analysis of myocilin mutations in 1703 glaucoma patients from five different populations. *Hum Mol Genet* 1999; **8**: 899–905.
- 27 Sheffield VC, Stone EM, Alward WL, Drack AV, Johnson AT, Streib LM *et al.* Genetic linkage of familial open angle glaucoma to chromosome 1q21-q31. *Nat Genet* 1993; **4**: 47–50.
- 28 Fingert JH, Stone EM, Sheffield VC, Alward WL. Myocilin glaucoma. *Surv Ophthalmol* 2002; **47**: 547–561.
- 29 Gong G, Kosoko-Lasaki O, Haynatzki GR, Wilson MR. Genetic dissection of myocilin glaucoma. *Hum Mol Genet* 2004; **13** Spec No 1: R91–R102.
- 30 Wiggs JL, Allingham RR, Vollrath D, Jones KH, De La Paz M, Kern J *et al.* Prevalence of mutations in TIGR/Myocilin in patients with adult and juvenile primary open-angle glaucoma. *Am J Hum Genet* 1998; **63**: 1549–1552.
- 31 Shimizu S, Lichter PR, Johnson AT, Zhou Z, Higashi M, Gottfredsdottir M *et al.* Age-dependent prevalence of mutations at the GLC1A locus in primary open-angle glaucoma. *Am J Ophthalmol* 2000; **130**: 165–177.
- 32 Yen YC, Yang JJ, Chou MC, Li SY. Identification of mutations in the myocilin (MYOC) gene in Taiwanese patients with juvenile-onset open-angle glaucoma. *Mol Vis* 2007; **13**: 1627–1634.
- 33 Johnson AT, Richards JE, Boehnke M, Stringham HM, Herman SB, Wong DJ *et al.* Clinical phenotype of juvenile-onset primary open-angle glaucoma linked to chromosome 1q. *Ophthalmology* 1996; **103**: 808–814.
- 34 Richards JE, Lichter PR, Boehnke M, Uro JLA, Torrez D, Wong D *et al.* Mapping of a gene for autosomal dominant juvenile-onset open-angle glaucoma to chromosome 1q. *Am J Hum Genet* 1994; **54**: 62–70.
- 35 Graul TA, Kwon YH, Zimmerman MB, Kim CS, Sheffield VC, Stone EM *et al.* A case-control comparison of the clinical characteristics of glaucoma and ocular hypertensive patients with and without the myocilin Gln368Stop mutation. *Am J Ophthalmol* 2002; **134**: 884–890.
- 36 Craig JE, Baird PN, Healey DL, McNaught AI, McCartney PJ, Rait JL *et al.* Evidence for genetic heterogeneity within eight glaucoma families, with the GLC1A Gln368STOP mutation being an important phenotypic modifier. *Ophthalmology* 2001; **108**: 1607–1620.
- 37 Jacobson N, Andrews M, Shepard AR, Nishimura D, Searby C, Fingert JH *et al.* Non-secretion of mutant proteins of the glaucoma gene myocilin in cultured trabecular meshwork cells and in aqueous humor. *Hum Mol Genet* 2001; **10**: 117–125.
- 38 Joe MK, Sohn S, Hur W, Moon Y, Choi YR, Kee C. Accumulation of mutant myocilins in ER leads to ER stress and potential cytotoxicity in human trabecular meshwork cells. *Biochem Biophys Res Commun* 2003; **312**: 592–600.
- 39 Gobeil S, Rodrigue MA, Moisan S, Nguyen TD, Polansky JR, Morissette J *et al.* Intracellular sequestration of hetero-oligomers formed by wild-type and glaucoma-causing myocilin mutants. *Invest Ophthalmol Vis Sci* 2004; **45**: 3560–3567.
- 40 Liu Y, Vollrath D. Reversal of mutant myocilin non-secretion and cell killing: implications for glaucoma. *Hum Mol Genet* 2004; **13**: 1193–1204.
- 41 Tamm ER. The Functional Role of Myocilin in Glaucoma. In: Tombran-Tink J, Barnstable CJ, Shields MB (eds). *Ophthalmology Research: Mechanisms of the Glaucomas*. Humana Press: Totowa, 2009 pp 219–231.
- 42 Kwon YH, Fingert JH, Kuehn MH, Alward WL. Primary open-angle glaucoma. *N Engl J Med* 2009; **360**: 1113–1124.
- 43 Senatorov V, Malyukova I, Fariss R, Wawrousek EF, Swaminathan S, Sharan SK *et al.* Expression of mutated

- mouse myocilin induces open-angle glaucoma in transgenic mice. *J Neurosci* 2006; **26**: 11903–11914.
- 44 Zhou Y, Grinchuk O, Tomarev SI. Transgenic mice expressing the Tyr437His mutant of human myocilin protein develop glaucoma. *Invest Ophthalmol Vis Sci* 2008; **49**: 1932–1939.
- 45 Paper W, Kroeber M, Heersink S, Stephan DA, Fuchshofer R, Russell P *et al*. Elevated amounts of myocilin in the aqueous humor of transgenic mice cause significant changes in ocular gene expression. *Exp Eye Res* 2008; **87**: 257–267.
- 46 Sarfarazi M, Child A, Stoilova D, Brice G, Desai T, Trifan OC *et al*. Localization of the fourth locus (GLC1E) for adult-onset primary open-angle glaucoma to the 10p15-p14 region. *Am J Hum Genet* 1998; **62**: 641–652.
- 47 Alward WL, Kwon YH, Kawase K, Craig JE, Hayreh SS, Johnson AT *et al*. Evaluation of optineurin sequence variations in 1,048 patients with open-angle glaucoma. *Am J Ophthalmol* 2003; **136**: 904–910.
- 48 Aung T, Ebenezer ND, Brice G, Child AH, Prescott Q, Lehmann OJ *et al*. Prevalence of optineurin sequence variants in adult primary open angle glaucoma: implications for diagnostic testing. *J Med Genet* 2003; **40**: e101.
- 49 McDonald KK, Abramson K, Beltran MA, Ramirez MG, Alvarez M, Ventura A *et al*. Myocilin and optineurin coding variants in Hispanics of Mexican descent with POAG. *J Hum Genet* 2010; **55**: 697–700.
- 50 Fuse N, Takahashi K, Akiyama H, Nakazawa T, Seimiya M, Kuwahara S *et al*. Molecular genetic analysis of optineurin gene for primary open-angle and normal tension glaucoma in the Japanese population. *J Glaucoma* 2004; **13**: 299–303.
- 51 Umeda T, Matsuo T, Nagayama M, Tamura N, Tanabe Y, Ohtsuki H. Clinical relevance of optineurin sequence alterations in Japanese glaucoma patients. *Ophthalmic Genet* 2004; **25**: 91–99.
- 52 Toda Y, Tang S, Kashiwagi K, Mabuchi F, Iijima H, Tsukahara S *et al*. Mutations in the optineurin gene in Japanese patients with primary open-angle glaucoma and normal tension glaucoma. *Am J Med Genet A* 2004; **125A**: 1–4.
- 53 Weisschuh N, Neumann D, Wolf C, Wissinger B, Gramer E. Prevalence of myocilin and optineurin sequence variants in German normal tension glaucoma patients. *Mol Vis* 2005; **11**: 284–287.
- 54 Wiggs JL, Auguste J, Allingham RR, Flor JD, Pericak-Vance MA, Rogers K *et al*. Lack of association of mutations in optineurin with disease in patients with adult-onset primary open-angle glaucoma. *Arch Ophthalmol* 2003; **121**: 1181–1183.
- 55 Jansson M, Wadelius C, Rezaie T, Sarfarazi M. Analysis of rare variants and common haplotypes in the optineurin gene in Swedish glaucoma cases. *Ophthalmic Genet* 2005; **26**: 85–89.
- 56 Mukhopadhyay A, Komatireddy S, Acharya M, Bhattacharjee A, Mandal AK, Thakur SK *et al*. Evaluation of Optineurin as a candidate gene in Indian patients with primary open angle glaucoma. *Mol Vis* 2005; **11**: 792–797.
- 57 Caixeta-Umbelino C, de Vasconcellos JP, Costa VP, Kasahara N, Della Paolera M, de Almeida GV *et al*. Lack of association between optineurin gene variants T34T, E50K, M98K, 691\_692insAG and R545Q and primary open angle glaucoma in Brazilian patients. *Ophthalmic Genet* 2009; **30**: 13–18.
- 58 De Marco N, Buono M, Troise F, Diez-Roux G. Optineurin increases cell survival and translocates to the nucleus in a Rab8-dependent manner upon an apoptotic stimulus. *J Biol Chem* 2006; **281**: 16147–16156.
- 59 Chi ZL, Akahori M, Obazawa M, Minami M, Noda T, Nakaya N *et al*. Overexpression of optineurin E50K disrupts Rab8 interaction and leads to a progressive retinal degeneration in mice. *Hum Mol Genet* 2010; **19**: 2606–2615.
- 60 Fingert JH, Robin AL, Stone JL, Roos B, Davis LK, Scheetz TA *et al*. Copy number variations on chromosome 12q14 patients with normal tension glaucoma. *Hum Mol Genet* 2011, e-pub ahead of print 29 March 2011; doi:10.1093/hmg/ddr123.
- 61 Morton S, Hesson L, Pegg M, Cohen P. Enhanced binding of TBK1 by an optineurin mutant that causes a familial form of primary open angle glaucoma. *FEBS Lett* 2008; **582**: 997–1002.
- 62 Monemi S, Spaeth G, Dasilva A, Popinchalk S, Ilitchev E, Liebmann J *et al*. Identification of a novel adult-onset primary open-angle glaucoma (POAG) gene on 5q22.1. *Hum Mol Genet* 2005; **14**: 725–733.
- 63 Hauser MA, Allingham RR, Linkroum K, Wang J, LaRocque-Abramson K, Figueiredo D *et al*. Distribution of WDR36 DNA sequence variants in patients with primary open-angle glaucoma. *Invest Ophthalmol Vis Sci* 2006; **47**: 2542–2546.
- 64 Hewitt AW, Dimasi DP, Mackey DA, Craig JE. A glaucoma case-control study of the WDR36 Gene D658G sequence variant. *Am J Ophthalmol* 2006; **142**: 324–325.
- 65 Fingert JH, Alward WL, Kwon YH, Shankar SP, Andorf JL, Mackey DA *et al*. No association between variations in the WDR36 gene and primary open-angle glaucoma. *Arch Ophthalmol* 2007; **125**: 434–436.
- 66 Pang CP, Fan BJ, Canlas O, Wang DY, Dubois S, Tam PO *et al*. A genome-wide scan maps a novel juvenile-onset primary open angle glaucoma locus to chromosome 5q. *Mol Vis* 2006; **12**: 85–92.
- 67 Kramer PL, Samples JR, Monemi S, Sykes R, Sarfarazi M, Wirtz MK. The role of the WDR36 gene on chromosome 5q22.1 in a large family with primary open-angle glaucoma mapped to this region. *Arch Ophthalmol* 2006; **124**: 1328–1331.
- 68 Miyazawa A, Fuse N, Mengkegale M, Ryu M, Seimiya M, Wada Y *et al*. Association between primary open-angle glaucoma and WDR36 DNA sequence variants in Japanese. *Mol Vis* 2007; **13**: 1912–1919.
- 69 Fan BJ, Wang DY, Cheng CY, Ko WC, Lam SC, Pang CP. Different WDR36 mutation pattern in Chinese patients with primary open-angle glaucoma. *Mol Vis* 2009; **15**: 646–653.
- 70 Footz TK, Johnson JL, Dubois S, Boivin N, Raymond V, Walter MA. Glaucoma-associated WDR36 variants encode functional defects in a yeast model system. *Hum Mol Genet* 2009; **18**: 1276–1287.
- 71 Chi ZL, Yasumoto F, Sergeev Y, Minami M, Obazawa M, Kimura I *et al*. Mutant WDR36 directly affects axon growth of retinal ganglion cells leading to progressive retinal degeneration in mice. *Hum Mol Genet* 2010; **19**: 3806–3815.
- 72 Meguro A, Inoko H, Ota M, Mizuki N, Bahram S. Genome-wide association study of normal tension glaucoma: common variants in SRBD1 and ELOVL5 contribute to disease susceptibility. *Ophthalmology* 2010; **117**: 1331–1338 e1335.
- 73 Kuehn MH, Wang K, Roos B, Stone EM, Kwon YH, Alward WLM *et al*. Chromosome 7q31 POAG locus: ocular expression of caveolins and lack of association with POAG in a US cohort. *Mol Vis* 2011; **17**: 430–435.



- 74 Parton RG, Simons K. The multiple faces of caveolae. *Nat Rev Mol Cell Biol* 2007; **8**: 185–194.
- 75 Allingham RR, Liu Y, Rhee DJ. The genetics of primary open-angle glaucoma: a review. *Exp Eye Res* 2009; **88**: 837–844.
- 76 Alsbirk PH. Corneal thickness. II. Environmental and genetic factors. *Acta Ophthalmol (Copenh)* 1978; **56**: 105–113.
- 77 Toh T, Liew SH, MacKinnon JR, Hewitt AW, Poulsen JL, Spector TD *et al*. Central corneal thickness is highly heritable: the twin eye studies. *Invest Ophthalmol Vis Sci* 2005; **46**: 3718–3722.
- 78 Armaly MF. Genetic determination of cup/disc ratio of the optic nerve. *Arch Ophthalmol* 1967; **78**: 5–43.
- 79 Schwartz TJ, Reuling FH, Feinleib M. Size of the physiologic cup of the optic nerve head: heredity and environmental factors. *Arch Ophthalmol* 1975; **93**: 776–780.
- 80 Klein BE, Klein R, Lee KE. Heritability of risk factors for primary open-angle glaucoma: the Beaver Dam Eye Study. *Invest Ophthalmol Vis Sci* 2004; **45**: 59–62.
- 81 Chang TC, Congdon NG, Wojciechowski R, Munoz B, Gilbert D, Chen P *et al*. Determinants and heritability of intraocular pressure and cup-to-disc ratio in a defined older population. *Ophthalmology* 2005; **112**: 1186–1191.
- 82 Armaly MF. The genetic determination of ocular pressure in the normal eye. *Arch Ophthalmol* 1967; **78**: 187–192.
- 83 Levene RZ, Workman PL, Broder SW, Hirschhorn K. Heritability of ocular pressure in normal and suspect ranges. *Arch Ophthalmol* 1970; **84**: 730–734.
- 84 van Koolwijk LM, Despriet DD, van Duijn CM, Pardo Cortes LM, Vingerling JR, Aulchenko YS *et al*. Genetic contributions to glaucoma: heritability of intraocular pressure, retinal nerve fiber layer thickness, and optic disc morphology. *Invest Ophthalmol Vis Sci* 2007; **48**: 3669–3676.
- 85 Lu Y, Dimasi DP, Hysi PG, Hewitt AW, Burdon KP, Toh T *et al*. Common genetic variants near the brittle cornea syndrome locus ZNF469 influence the blinding disease risk factor central corneal thickness. *PLoS Genet* 2010; **6**: e1000947.
- 86 Vitart V, Bencic G, Hayward C, Skunca Herman J, Huffman J, Campbell S *et al*. New loci associated with central cornea thickness include COL5A1, AKAP13 and AVGR8. *Hum Mol Genet* 2010; **19**: 4304–4311.
- 87 Vithana EN, Aung T, Khor CC, Cornes BK, Tay WT, Sim X *et al*. Collagen-related genes influence the glaucoma risk factor, central corneal thickness. *Hum Mol Genet* 2011; **20**: 649–658.
- 88 Abu A, Frydman M, Marek D, Pras E, Nir U, Reznik-Wolf H. Deleterious mutations in the zinc-finger 469 gene cause brittle cornea syndrome. *Am J Hum Genet* 2008; **82**: 1217–1222.
- 89 Gould DB, Reedy M, Wilson LA, Smith RS, Johnson RL, John SW. Mutant myocilin nonsecretion *in vivo* is not sufficient to cause glaucoma. *Mol Cell Biol* 2006; **26**: 8427–8436.